Partnerships with the world's most forward-thinking pharmaceutical companies

Our track record of excellence means that we partner with some of the world's most innovative and established biotechnology and pharmaceutical companies.

Our business model is to seek licensing and collaborative opportunities for our programmes when they have reached the candidate drug or IND phase of pre-clinical development.

Interested companies are encouraged to contact us to receive further information and to receive a more detailed R&D information pack.

Sentinel Oncology also considers in-licensing early stage programmes and would encourage organisations and institutions to contact us with any relevant information for review.

For further information on partnering options, please get in touch.

Contact us.